<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97585">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082457</url>
  </required_header>
  <id_info>
    <org_study_id>YKP10811</org_study_id>
    <nct_id>NCT02082457</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation</brief_title>
  <acronym>YKP</acronym>
  <official_title>Multi-center, Randomized, Double Blinded, Placebo-controlled, Phase II Trial to Assess the Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <authority>Ministry of Food and Drug Safety : South Korea</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable
      Bowel Syndrome With Constipation. The difference of responder rate between test group (10,
      20 and 40mg) and placebo will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Abdominal pain intensity &amp; stool frequency responder</measure>
    <time_frame>12weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>an improvement of equl and more than 30% from baseline in the average of the daily worst abdominal pain score and an increase of equal and more than 1 CSBM from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>subject global assessment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>the dgree of symptom relief on abdominal pain, bloating, stool frequency, stool consitency, etc.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>YKP10811 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YKP10811 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YKP10811 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YKP10811 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YKP10811 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YKP10811 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YKP10811 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YKP10811 10mg , 20mg, 40mg and placebo</intervention_name>
    <description>YKP10811 10mg , 20mg, 40mg or placebo administered orally once a day during 12 weeks</description>
    <arm_group_label>YKP10811 placebo</arm_group_label>
    <arm_group_label>YKP10811 10mg</arm_group_label>
    <arm_group_label>YKP10811 20mg</arm_group_label>
    <arm_group_label>YKP10811 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. more than 18 years old

          2. patients met with ROME III criteria for C-type IBS

        Exclusion Criteria:

          -  pregnancy or lactation

          -  a history of surgery for gastrointestinal tract

          -  a history of gestrointestinal bleeding, diverticulitis and ileus within 1 year of
             screening visit

          -  inflammatory bowel disease or malignant tumor within 5 years of screening visit

          -  taking drugs that could have impact on efficacy assessment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo jin Park, professional</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beom jun Seo, manager</last_name>
    <phone>82-2-2008-2129</phone>
    <email>seobj@sk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gang Nam Severance Hospital</name>
      <address>
        <city>Gang nam Gu</city>
        <state>Seoul</state>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyojin Park, MD.PhD.</last_name>
      <phone>82-2-2008-2129</phone>
    </contact>
    <investigator>
      <last_name>Hyo jin Park, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Constipation</keyword>
  <keyword>C-IBS</keyword>
  <keyword>YKP</keyword>
  <keyword>Multi-center</keyword>
  <keyword>Randomized</keyword>
  <keyword>Double blinded</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Phase II trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
